MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jamda.2026.106214

Медицинская библиотека · Journal of the American Medical Directors Association · 2026

Durability of Clinical Protection in Nursing Home Residents Following Monovalent KP.2 SARS-CoV-2 Vaccination.

Gravenstein Stefan, DeVone Frank, Abul Yasin, Halladay Christopher W, Rudolph James L, Nugent Clare, Skov Benjamin, Yavuz Selma, Canaday David H, McConeghy Kevin W

Сравнительное исследованиеСтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVES

Nursing home residents received updated monovalent SARS-CoV-2 vaccines to protect them from the most recently emerging SARS-CoV-2 variants. We evaluated nursing home residents for the extent and durability of protection from hospitalization or death after monovalent KP.2 vaccination.

DESIGN

Retrospective cohort study using a target trial emulation design. We conducted a sequential, daily comparison of those who did and did not receive a KP.2 vaccination during the study period. Residents who received KP.2 were matched to unvaccinated residents based on index date and propensity scores incorporating demographics, vaccination status, and basic clinical characteristics.

SETTING AND

PARTICIPANTS

Long-stay residents living in Veterans Affairs nursing homes between September 18, 2024, and October 30, 2024.

METHODS

The primary exposure was KP.2 vaccination vs no SARS-CoV-2 vaccine during the study period. The primary outcome was a test-confirmed SARS-CoV-2 infection. Secondary outcome was composite outcome of COVID-19-associated hospitalizations within 21 days or death within 30 days of confirmed infection.

RESULTS

Among eligible residents, a matched cohort of 1711 paired person trials were created (average age 76, 95% male, 28% African American). Vaccine effectiveness against COVID-19 infection was 38% at week 12 (95% CI, 13%-56%) and 4% at week 18 (95% CI, -30 to 29%). Vaccine effectiveness against hospitalization or death was 77% at week 12 (95% CI, 60%-90%) and 53% at week 18 (95% CI, 21%-71%).

CONCLUSION AND IMPLICATIONS: Vaccination with the KP.2 updated SARS-CoV-2 vaccine provided significant clinical protection against hospitalization or death among nursing home residents. This protection started to wane within a few months of vaccination, mirroring antibody decline reported in other studies. Our findings support consideration of twice-annual vaccination strategy to optimize protection in this vulnerable population.

Для цитирования: Gravenstein Stefan, DeVone Frank, Abul Yasin, Halladay Christopher W, Rudolph James L, Nugent Clare, Skov Benjamin, Yavuz Selma, Canaday David H, McConeghy Kevin W. Durability of Clinical Protection in Nursing Home Residents Following Monovalent KP.2 SARS-CoV-2 Vaccination.. Journal of the American Medical Directors Association. 2026. DOI: 10.1016/j.jamda.2026.106214.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.